CagriSema cardiovascular trial publishes design as outcome results remain pending

A report published October 6 in the American Heart Journal describes the design and baseline population of REDEFINE 3, a cardiovascular outcomes trial of CagriSema. The study addresses a consequential question for metabolic medicine: whether the combination can protect people already living with cardiovascular disease. The new publication supplies the framework for answering that question, but no treatment-outcome comparison.

CagriSema combines cagrilintide, which activates amylin receptors, with the GLP-1 receptor agonist semaglutide. The report describes 7,076 randomized adults across 575 sites in 24 countries. Their mean age was 66 years, and 61% had type 2 diabetes. This population makes the eventual results relevant to preventing further illness in adults with substantial existing disease.

### What the trial is testing

REDEFINE 3 is randomized, blinded and placebo-controlled. Participants have established cardiovascular disease and a body mass index of at least 25, with or without diabetes. Both treatment groups receive standard care, allowing investigators to assess the additional effect of the study treatment.

The publication distinguishes two objectives. The cardiovascular safety assessment tests noninferiority on a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke. The efficacy assessment tests superiority on an expanded composite that also includes revascularization, a procedure to restore blood flow.

Those statistical questions have different meanings. Noninferiority asks whether a treatment avoids being worse than its comparator beyond a specified margin. Superiority asks whether it performs better. Meeting a safety objective would therefore not, by itself, establish cardiovascular benefit.

### The registry adds context—and some differences

The ClinicalTrials.gov record identifies Novo Nordisk as sponsor and lists the Phase 3 study as active but no longer recruiting. Its August 31 update estimates primary completion in September 2027 and study completion in October 2027. These are projected milestones, not promised dates for public results.

The registry lists time to a first cardiovascular death, nonfatal heart attack or nonfatal stroke as its primary outcome. Other registered measures include kidney outcomes, body weight, blood pressure and serious adverse events. These additional assessments could help characterize the balance of benefits and harms once treatment comparisons become available.

The public sources are not identical snapshots. ClinicalTrials.gov lists actual enrollment of 7,101, whereas the paper’s abstract reports 7,076 randomized participants. The accessible records do not explain that difference. Accordingly, the publication’s population count should not be silently substituted for the registry’s enrollment figure, or vice versa.

### What this means for healthspan research

A cardiovascular outcomes trial can address consequences that matter directly to patients: surviving disease and avoiding further major events. Changes in weight or blood sugar alone cannot answer every question about those outcomes. The practical importance of REDEFINE 3 lies in its planned comparison of clinical events over extended follow-up.

For now, however, there is no basis in this report for calculating a cardiovascular risk reduction, estimating how many people would benefit, or concluding that the combination improves survival. Baseline characteristics describe who entered a study; they do not reveal what treatment achieved.

The eventual findings will also need to be interpreted within the enrolled population. A trial in adults with established cardiovascular disease cannot automatically establish preventive benefits for otherwise healthy people interested in longevity. Absolute event rates, uncertainty around treatment effects, adverse events and treatment discontinuation will be essential to judging its clinical value.